- Details
- Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes between older and younger patients, revealing that older patients exhibit a slightly diminished benefit from intensified treatments compared to their younger counterparts. Despite this, the...
|
- Details
- Michael Williams and Mark Fleming discuss their collaborative approach in managing patients with metastatic prostate cancer. Drs. Williams and Fleming emphasize the importance of multidisciplinary care, sharing a case of a patient with high-volume disease treated with an oral LHRH antagonist and enzalutamide. They highlight the need for open communication and decision-making between specialties to...
|
- Details
- Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...
|
- Details
- Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. The study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 344,000 patients globally, examines the application of doublets and triplets in treatment, revea...
|
- Details
- Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients' responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study's methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide com...
|
- Details
- Zach Klaassen converses with Daniel Saltzstein about the collaborative approach to treating metastatic hormone-sensitive prostate cancer with triplet therapy or maximum androgen blockade. Dr. Saltzstein describes their unique practice set up in San Antonio, where a medical oncologist is part of their urology team. This shared patient focus facilitates seamless collaboration and treatment managemen...
|
- Details
- Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive prostate cancer with triplet therapy. Drs. Park and Malone, who met through shared patients and conferences, emphasize the importance of co-management in treating these complex cases. They discuss patient selection for tripl...
|
- Details
- Zach Klaassen engages with Vahan Kassabian and Sreekanth to discuss the continuum of care for patients with metastatic hormone-sensitive prostate cancer, particularly in the context of triplet therapy based on the ARASENS data. The conversation reveals their longstanding professional relationship, developed through mutual patients and a shared interest in urological oncology. They discuss the logi...
|
- Details
- Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss the amended AUA guidelines for advanced prostate cancer, focusing on triplet therapy for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castrate-resistant prostate cancer (M0 CRPC). They delve into the role of triplet therapy in mHSPC, examining its benefits across disease volume and risk subgroups, as evidenced by the ARASENS and PE...
|
